BSX’s 4Q17 earnings results
On February 1, 2018, Boston Scientific (BSX) released its 4Q17 and 2017 earnings results. The company’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
On a YoY (year-over-year) basis, the company reported sales growth of ~9.9% in 4Q17. For the whole of 2017, Boston Scientific reported sales growth of 7.9% on total sales of $9.1 billion. On February 1, BSX stock registered a fall of ~1.2%.
4Q17 sales results
Boston Scientific reported sales of ~$2.41 billion in 4Q17. These results exceeded the company’s guidance range of 5%–6% operational sales growth, coming in at ~8% excluding currency impacts. Strong performances across its business segments and geographies drove the company’s sales growth. Its 4Q17 sales saw an impact of $37 million due to currency tailwinds.
Boston Scientific’s 4Q17 organic sales growth came in at ~7%. Its acquisitions of Symetis and Endochoice had an impact of ~1.3% on its 4Q17 sales.
Sales by geography
Boston Scientific reported balanced global growth in 4Q17. In the United States, the company witnessed sales growth of ~8% on an organic basis. The EMEA (Europe, the Middle East, and Africa) region also registered a rise of ~8% in its sales in 4Q17. In emerging markets, Boston Scientific’s sales growth came in at ~13% led by strong YoY sales growth of ~19% in China.
Next, we’ll take a look at BSX’s MedSurg business’s recent performance and its 2018 growth drivers.